

SUPPORT FOR THE AMENDMENTS

Newly-added Claims 15-21 are supported the specification, especially Example 240 at page 187, and the original claims. Accordingly, no new matter is believed to have been added to the present application by the amendments submitted above.

REMARKS

Claims 1-4, 6, 8, 13 and 14-21 are pending, upon entry of the amendment submitted above. Favorable reconsideration is respectfully requested.

Applicants would like to thank Examiner Morris for the telephone exchange on May 24, 2006, in which the Examiner indicated that a supplemental amendment as submitted above would be considered.

Claims 15-21 have been added. Independent Claim 15 is directed to the compound described in Example 240 at page 187 of the specification. That compound is within the scope of Claim 1. In fact, the compound (N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea) was explicitly recited in Claim 4 prior to the amendment submitted above. The compound has been removed from Claim 4. Dependent Claims 19-21 correspond to Claims 6, 8 and 9, respectively.

Applicants submit that the present application is in condition for allowance. Early notice to this effect is earnestly solicited.


Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)



James J. Kelly, Ph.D.
Attorney of Record
Registration No. 41,504